Searchable abstracts of presentations at key conferences in endocrinology

ea0064019 | Androgen metabolism during weight loss in men with obesity | BES2019

Androgen metabolism during weight loss in men with obesity

Frederique Van de Velde , Koen Deventer , Wim Van Gansbeke , Peter Van Eenoo , Ieter Van Renterghem , Tom Fiers , Marc Kaufman Jean , Yves Van Nieuwenhove , Bruno Lapauw

Background: Men with obesity often have low total and, with increasing adiposity, also free testosterone (T) levels, which can partially restore when they lose weight. Although this is in part explained by lower sex-hormone binding globulin (SHBG) production and hypothalamic-pituitary downregulation, it is still not fully unraveled whether changes in androgen metabolization contribute to this phenomenon.Aim: Investigating metabolisation of sex steroids d...

ea0063gp138 | Obesity | ECE2019

Androgen metabolism during weight loss in men with obesity

Velde Frederique Van de , Deventer Koen , Gansbeke Wim Van , Eenoo Peter Van , Renterghem Pieter Van , Fiers Tom , Kaufman Jean-Marc , Nieuwenhove Yves Van , Lapauw Bruno

Background: Men with obesity often have low total and, with increasing adiposity, also free testosterone (T) levels, which can partially restore when they lose weight. Although this is in part explained by lower sex-hormone binding globulin (SHBG) production and hypothalamic-pituitary downregulation, it is still not fully unraveled whether changes in androgen metabolization contribute to this phenomenon.Aim: Investigating metabolisation of sex steroids d...

ea0063p652 | Interdisciplinary Endocrinology 1 | ECE2019

Restoring the sleep disruption by blue light emitting screen use in adolescents: a randomized controlled trial

Meijden Wisse P van der , Stenvers Dirk Jan , Kerkhof Linda van , Nierop Lotte van , Steeg Harry van , Bisschop Peter H , Someren Eus J van , Kalsbeek Andries

Introduction: Adolescents spend much time using blue-light emitting screen devices such as smartphones, tablets and computers. Blue light affects the central circadian clock in the suprachiasmatic nucleus (SCN) as well as melatonin secretion by the pineal gland. Screen use in adolescents strongly associates with reduced sleep quality and sleep duration. However, there is a lack of intervention studies that reduce blue light exposure due to screen use in adolescents.<p clas...

ea0073aep280 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Effects of Glucagon-Like-Peptide-1 analogue treatment in genetic obesity

Welling Mila , Groot Cornelis de , Kleinendorst Lotte , Bibian van der Voorn , Burgerhart Jansteven , Eline van der Valk , Haelst Mieke van , Erica van den Akker , Rossum Elisabeth van

IntroductionObesity is highly prevalent, comes with serious health burden and is difficult to treat. In a minority, there is a genetic cause for the obesity. In these patients, therapy-resistant obesity is often observed despite intensive lifestyle treatment. Moreover, it is still unclear whether bariatric surgery is less successful in genetic obesity. Liraglutide is a Glucagon-Like-Peptide-1 (GLP-1) receptor agonist or GLP-1 analogue, showing positive e...

ea0084ps2-07-59 | Graves’ Disease 1 | ETA2022

TPO antibody status prior to first radioactive iodine therapy as a predictive parameter for early hypothyroidism in graves’ disease

Verdickt Sebastien , Van Nes Falco , Moyson Carolien , Maes Toon , Van Crombrugge Paul , Van den Bruel Annick , Decallonne Brigitte

Introduction: Several studies identified pre-treatment parameters that could help in the prediction of the thyroid functional outcome after radioactive iodine therapy (RAI) in Graves’ disease. However, the role of the thyroid peroxidase antibody (TPO Ab) status is not well studied.Objectives: We investigated if a positive TPO Ab status before radioactive iodine (RAI) therapy in patients with Graves’ hyperthyroidism is a predictive factor for de...

ea0088013 | Abstracts | BES2022

TPO antibody status prior to first radioactive iodine therapy as a predictive parameter for hypothyroidism in Graves’ disease

Sebastien Verdickt , Nes Falco Van , Carolien Moyson , Toon Maes , Crombrugge Paul Van , den Bruel Annick Van , Brigitte Decallonne

Objective: We investigated if a positive thyroid peroxidase antibody (TPO Ab) status before radioactive iodine (RAI) therapy in patients with Graves’ hyperthyroidism is a predictive factor for developing hypothyroidism after RAI.Methods: We performed a retrospective study of patients with Graves’ hyperthyroidism with known TPO Ab status, receiving a first administration of RAI. Patients from 4 thyroid outpatient centres in Belgium receiving a f...

ea0090p31 | Calcium and Bone | ECE2023

Bone mineral density in children and adolescents with Cystic Fibrosis

Tamer Gizem , Gerardus Maria Arets Hubertus , Kors van der Ent Cornelis , Margo van Santen Hanneke , Jacoba van der Kamp Hetty

Background: Bone health can be affected in (young) adults with Cystic Fibrosis (CF) due to different risk factors in childhood. We aimed to analyze the prevalence of low bone mineral density (BMD) during childhood in patients with CF, its risk factors and course in time.Methods: A longitudinal prospective cohort study was performed in children with CF aged 8-18. Anthropometric, DEXA scans and endocrine data were collected. BMD z-scores were adjusted for ...

ea0090ep765 | Pituitary and Neuroendocrinology | ECE2023

‘Needless needles’: Can GH injections be prevented by treatment of deep vitamin D deficiency?

Davidse Kirsten , van Eck Judith , van den Akker Erica , van der Lely Aart-Jan , de Graaff Laura

Introduction: Growth hormone (GH) is not only important for growth during childhood. Also, for (young) adults, growth hormone is important for bone mass, muscle strength and metabolism. GH deficiency (GHD) is a condition that can cause a broad range of adult health issues, if left untreated. Therefore on one hand, it is important to confirm and treat GHD after transfer to adult care. On the other hand, the personal and financial burden of unnecessary growth hormone in...

ea0049oc9.1 | Thyroid Disease 2 | ECE2017

Thyroid function and metabolic syndrome: results from the population-based LifeLines Cohort study

Wolffenbuttel Bruce , Wouters Hanneke , Slagter Sandra , van Waateringe Robert , van Vliet-Ostaptchouk Jana , Links Thera , van der Klauw Melanie

Background: The metabolic syndrome (MetS) is a combination of unfavourable health factors including abdominal obesity, dyslipidaemia, hypertension and impaired fasting glucose. Several small-scale studies have reported a relationship between thyroid function and some MetS components or suggested that serum FT3 levels within the normal range were independently associated with insulin resistance. We assessed how thyroid function relates to the prevalence of MetS in a large popul...

ea0037ep742 | Pituitary: clinical | ECE2015

Tumour regrowth in growth hormone deficient adults with non-functioning pituitary adenomas using growth hormone replacement therapy – a sub-analysis from the Dutch National Registry of growth hormone treatment in Adults

van Varsseveld Nadege , van Bunderen Christa , Franken Anton , Koppeschaar Hans , van der Lely Aart Jan , Drent Madeleine

Objective: Growth hormone treatment (GHT) is a widely accepted treatment in growth hormone deficient (GHD) adults with nonfunctioning pituitary adenoma (NFPAs). However, concerns remain about the safety of GHT, because of its potentially stimulating effect on tumour (re)growth. The aim of this study was to evaluate tumour progression in NFPA patients using GHT.Patients and methods: From the Dutch National Registry of growth hormone treatment in adults, a...